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There is a clear need for new therapeutics to treat alcoholism. Here, we test our hypothesis that selective inhibitors of neuronal calcium
channelswill reduce ethanol consumptionand intoxication, basedonourprevious studiesusingknock-outmice andcell culture systems.
We demonstrate that pretreatment with the novel mixed N-type and T-type calcium channel antagonist 1-(6,6-bis(4-
fluorophenyl)hexyl)-4-(3,4,5-trimethoxybenzyl)piperazine (NP078585) reduced ethanol intoxication. NP078585 also attenuated the re-
inforcing and rewarding properties of ethanol, measured by operant self-administration and the expression of an ethanol conditioned
place preference, and abolished stress-induced reinstatement of ethanol seeking. NP078585 did not affect alcohol responses in mice
lacking N-type calcium channels. These results suggest that selective calcium channel inhibitorsmay be useful in reducing acute ethanol
intoxication and alcohol consumption by human alcoholics.
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Introduction
Alcohol abuse and alcoholism are significant public health issues.
In the United States, alcohol use disorders affect 14 million
people, costing approximately $184 billion per year because of
legal costs, lost wages, and medical costs (Kenna et al., 2004a,b).
To date, only three drugs have been approved for treatment in the
United States: disulfuram, naltrexone, and acamprosate. Use of
these drugs is constrained by their limited efficacy, side effects
and low patient compliance (Kenna et al., 2004b). It is estimated
that 40–70% of patients return to excessive drinking within a
year of treatment (Finney et al., 1996).
Given the current therapeutic limitations, there is a need to
develop new treatments for alcoholism. One approach is to iden-
tify targets of ethanol action and then determine whether modu-
lation of these targets can favorably alter behavioral responses to
alcohol. The function of voltage-gated calciumchannels is altered
at ethanol concentrations that affect humans (Walter and Mess-
ing, 1999). These channels mediate Ca2 entry into neurons in
response to changes in membrane potential, regulating neuronal
excitability, neurotransmitter release, and gene expression (Dun-
lap et al., 1995; Ghosh and Greenberg, 1995). They have been
classified as L-, N-, P/Q-, R-, and T-types according to their dis-
tinct electrophysiological and pharmacological properties (Dun-
lap et al., 1995).
High voltage-activated N-type calcium channels are exclu-
sively expressed in the nervous system where they contribute to
neurotransmitter release at a subset of central and peripheral
nerve terminals (Dubel et al., 1992; Snutch, 2005). We have
shown previously that acute ethanol exposure inhibits N-type
calcium channels (Solem et al., 1997), and chronic ethanol expo-
sure increases N-type channel function and density (McMahon
et al., 2000; Newton et al., 2005). Low voltage-activated T-type
calcium channels are biophysically distinct fromN-type channels
and contribute to rhythmic firing and bursting behaviors related
to processes such as sleep and epileptiform activity (Huguenard,
1996). Ethanol appears to have complex effects on T-type cur-
rents. In slices from the lateral geniculate nucleus, low concen-
trations (10 mM) of ethanol potentiate T-type currents,
whereas higher ethanol concentrations (20 mM) inhibit T-type
currents (Mu et al., 2003).
Mice lacking N-type calcium channels show reduced sensitiv-
ity to the hypnotic effect of ethanol and decreased voluntary eth-
anol consumption (Newton et al., 2004). This phenotype sug-
gested that pharmacological inhibition of N-type calcium
channels may be an effective strategy to reduce ethanol intoxica-
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tion and consumption. Here we tested this hypothesis pharma-
cologically using a novel mixed inhibitor of N-type and T-type
calcium channels, 1-(6,6-bis(4-fluorophenyl)hexyl)-4-(3,4,5-
trimethoxybenzyl)piperazine (NP078585) (Snutch et al., 2001,
2003; Xiao et al., 2008). NP078585 is the first generation com-
pound of a novel pharmacological class of orally bioavailable
N-type calcium channel inhibitors, some of which are in clinical
trials for the treatment of chronic pain (The Healthcare Market-
ing and Sales Network, March 20, 2006). Because alcoholism is a
heterogenous disease with many different facets, we assessed the ef-
fects ofNP078585 inmultiple animal paradigms thatmodel ethanol
intoxication, reinforcement, reward, and reinstatement (Egli, 2005).
Materials andMethods
Drugs. NP078585 (1-(6,6-bis(4-fluorophenyl)hexyl)-4-(3,4,5-trimeth-
oxybenzyl)piperazine (supplied byNeuromed Pharmaceuticals) was dis-
solved in polyethylene-glycol 400 vehicle (Fisher) by vortexing and brief
(5 min) sonication. All injections were given intraperitoneally.
NP078585 inhibits N-type calcium channels in vitro with a Kd of 110
nM.NP078585 also inhibits rat brain T-type calcium channels containing
CaV 3.1 subunits with a Kd of 200 nM, those containing CaV 3.2 sub-
units with a Kd of520 nM and those containing CaV3.3 subunits with a
Kd of250 nM. Kd values for the inhibition of P/Q channels containing
Cav2.1 and L-type calcium channels containingCav1.2 are 1450 and 2810
nM respectively. Intraperitoneal injection of rats or mice with NP078585
dissolved in polyethylene-glycol 400 results in brain concentrations suf-
ficient to inhibit N-type calcium channels within 30 min (Cmax  450
nM). Within 24 h, the concentration drops to 22.5 nM (rats) or below
detectable levels (mice). The full characterization and pharmacokinetics
of NP078585 are being published separately.
Animals.Wild-type and CaV2.2(/)mice lacking the pore forming
1 subunit of N-type calcium channels weremaintained on an F1 hybrid
C57BL/6J  129/S4 background (Newton et al., 2004). Wild-type mice
on this backgroundwere used for loss of righting reflex (LORR), rotarod,
and ethanol clearance studies. CaV2.2(/)mice were also included in
the LORR experiment. For place preference and locomotor studies, we
used wild-type DBA/2 mice (Taconic), as this strain has been repeatedly
shown to exhibit robust ethanol responses in both paradigms (Cunning-
ham et al., 1998; Lessov et al., 2001). For operant self-administration and
reinstatement studies we used Long–Evans rats (Harlan). Animal usewas
in accordance with institutional and National Institutes of Health guide-
lines. All experiments were performed with naive male mice or rats,
except rotarod studies, in which animals were tested first on a fixed speed
rotarod and then on an accelerating rotarod.
Locomotor activity in mice.Mice were individually habituated to open-
field chambers (Med Associates) in three 20 min sessions on consecutive
days. Each session was preceded by a saline injection. On the fourth day,
micewere givenNP078585 or vehicle and returned to their home cage for
30 min. They were then injected with ethanol or saline and placed in the
open field for 20 min. The presence of locomotor stimulation was deter-
mined for each treatment group by comparing the distance traveled on
the test day with distance traveled during the third habituation session by
paired, two-tailed t tests.
Rotarod. Mice were trained to remain on a fixed speed (12 rpm) ro-
tarod for 180 s (Ugo Basile). The following day each mouse was tested to
ensure it could stay on the rotarod for 180 s, and then injected with either
NP078585 or vehicle and retested 30 min later (time 0). Mice were then
injected with ethanol and retested every 15min for 1 h.Mice received 1.5
g/kg ethanol in the first test session (experiment 1) and 2 g/kg ethanol
10 d later (experiment 2). After an additional 25 d, they were tested on an
accelerating rotarod (3–30 rpm over 300 s) after injection of 2 g/kg eth-
anol (experiment 3). Mice that received NP078585 in experiment 1 re-
ceived vehicle in experiment 2 and thenNP078585 again in experiment 3,
resulting in a 35 d gap between repeat administration of NP078585.
Loss of the righting reflex. Mice were pretreated with vehicle or
NP078585 30 min before ethanol (4.0 g/kg). Loss of the righting reflex
was defined as amouse being unable to right itself three times within 30 s
after ethanol injection. After losing the righting reflex, mice were placed
on their backs and the time taken for them to regain the righting reflex
(i.e., being able to right themselves three times in 30 s) was measured.
Place conditioning. DBA/2 mice were trained in open-field chambers
(ENV-515, Med Associates) equipped with two-chamber place prefer-
ence inserts (ENV-517, Med Associates). One chamber consisted of a
mesh floor with white walls while the other chamber had a rod floor with
black walls. Chambers were separated by a manual guillotine door that
was closed during training andopenduring habituation and test sessions.
Before training, animals were habituated to the apparatus by allowing
them 30 min free access to both chambers. DBA/2 mice used in these
experiments did not display a baseline preference for either chamber
(data not shown). Thus, equal numbers of animals received the uncon-
ditioned stimuli in either chamber. To assess the effect of NP078585 on
the expression of an ethanol conditioned place preference (CPP), mice
were trained in a standard ethanol CPP paradigm (Newton et al., 2004;
Newton and Messing, 2007) consisting of eight 5 min conditioning ses-
sions, four with saline and four with ethanol (2 g/kg, i.p.). One condi-
tioning sessionwas given per day and sessions were alternated (saline 1 d,
ethanol the next). On the day after the final conditioning session, mice
were tested for CPP by allowing them 30 min access to both chambers.
NP078585 (25 mg/kg) or vehicle was given 30 min before the test and
mice remained in their home cage for those 30 min. Time spent in the
ethanol-paired side was compared with time spent in the saline-paired
side using aWilcoxon signed rank test (Newton et al., 2004; Newton and
Messing, 2007; Newton et al., 2007). To assess the effect of NP078585 on
the expression of a LiCl conditioned place aversion we used the same
protocol except that conditioning trials were 30 min and the test was 60
min. LiCl (3 mEq/kg, i.p.) was given in place of ethanol (Risinger and
Cunningham, 2000).
Operant ethanol self-administration. Long–Evans rats were trained to
lever press for ethanol in operant chambers (Med-Associates) according
to established methods with a 26 day sucrose fade in the home cage
(Burattini et al., 2006). Rats were then water deprived overnight and
trained to lever press in the operant chambers in an overnight session
with 2 active levers delivering 10% ethanol on an FR1 schedule. After the
overnight session they were given water in the home cage for 8 h. They
were again water deprived overnight and the following day placed in the
operant chambers for 45 min with only one (right) lever delivering 10%
ethanol on an FR1 schedule. The left lever was presented but was inactive
and pressing it did not result in any programmed consequence. They
were then allowed access to water for 1 h in the home cage. These 45 min
sessions after overnight water deprivation were continued for 3 d, after
which ad libitumwater access in the home cagewas restored. FR1 sessions
were continued 5 d/week (Monday through Friday) for 4 weeks. Baseline
responding was then established in 30 min sessions on an fixed-ratio 3
(FR3) schedule for 4 weeks (weeks 1–4, 20 sessions). Rats that failed to
demonstrate a mean daily ethanol intake of at least 0.3 g/kg/session by
week 4 were eliminated from the study. During the fifth week, animals
were habituated twice to vehicle injections in sessions 2 d apart. Injec-
tions were given in the home cage 30 min before entry into the operant
chambers. Remaining sessions that week were as in the previous 4 weeks.
During weeks 6–11, animals were given one injection per week of either
vehicle, 2.5 or 25 mg/kg NP078585, 30 min before entry into the operant
chambers. Drug treatment was in a random order, and each animal
received all concentrations twice, once a week on Thursdays. Data for
individual animals were averaged at each concentration of NP078585.
Throughout the baseline and test sections of the experiment, chambers
and reward ports were examined after every session for the presence of
unconsumed alcohol. None was observed.
Stress-induced reinstatement of operant ethanol self-administration. A
separate group of Long–Evans rats were trained in the operant paradigm
described above, including habituation to vehicle injection. Operant be-
havior was then extinguished during 6 weeks during which lever pressing
did not result in the delivery of ethanol but did activate the syringe pump.
After 6 weeks, responses on the active lever had reached10% of those
during the final week of ethanol delivery. Animals were divided into two
groups matched for responses during the final week of ethanol delivery
and the final week of extinction. Half the animals were injected with
vehicle and half were injected with 25 mg/kg NP078585. Only one injec-
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tion of either vehicle or NP078585 was given. Thirty minutes later, all
animals were injected with 2.5 mg/kg yohimbine in water. After an addi-
tional 30 min the animals were placed in the chambers for a 30 min
operant session using conditions identical to those used during extinc-
tion (Leˆ et al., 2005).
Locomotor activity in rats. To control for effects of NP078585 on the
general locomotor activity of Long–Evans rats, we used Med Associates
rat locomotor activity boxes (ENV-515). Rats were habituated to the
chambers over 4 daily 30 min sessions. On the fifth day, animals were
treated with the same combinations of vehicle, NP078585 (25 mg/kg,
i.p.) and yohimbine (2.5 mg/kg, i.p.) used in the operant self-
administration experiments.
Ethanol clearance. F1 hybrid C57BL/6J  129/S4 mice (n  8 per
group) were pretreated with vehicle (PEG-400) or NP078585 (25mg/kg,
i.p.), 30 min before 4 g/kg ethanol. Blood samples were then taken from
the tail 30, 90, and 180 min later. Serum alcohol concentrations were
determined using an Analox AM-1 analyzer (Analox Instruments).
Statistical analyses. All data are expressed as mean  SEM values.
Means were compared by two-tailed t tests or by ANOVA with post hoc
Bonferroni’s tests except, as noted above, for CPP studies where means
were compared by Wilcoxon signed rank tests.
Results
NP078585 attenuates the acute effects of ethanol
We examined the effect of NP078585 on ethanol-stimulated lo-
comotor activity (Fig. 1A). Ethanol (2 g/kg) caused a significant
stimulation in vehicle pretreated animals ( p 0.001). This stim-
ulation was abolished by pretreatment with 25 mg/kg NP078585
( p  0.5674) but not 2.5 mg/kg NP078585 ( p  0.001). Treat-
ment with NP078585 alone had no significant effect on locomo-
tor activity ( p 0.244).
We next examined whether NP078585 would decrease
ethanol-induced ataxia. On a fixed-speed rotarod NP078585 did
not affect ethanol-induced ataxia (data not shown). On the ac-
celerating rotarod, animals pretreated with 25 mg/kg NP078585
showed significantly reduced ataxia. A two-way ANOVA with a
between-subjects factor for treatment (NP078585 or vehicle) and
a within-subjects factor for time showed main effects of treat-
ment (F(1,92) 19.08; p 0.001) and time (F(6,92) 77.040; p
0.001) with an interaction between these two factors (F(6,92) 
4.483; p 0.001). Post hoc Bonferroni tests showed a significant
difference between vehicle and NP078585 treated animals at all
times except time 0, demonstrating that NP078585 alone did not
cause ataxia (Fig. 1B).
To confirm that NP078585 was at least partially acting
through N-type calcium channels, we assessed the effect of
NP078585 on ethanol-induced (4 g/kg, i.p.) LORR in mice lack-
ing N-type calcium channels. Confirming previous work (New-
ton et al., 2004), these mice showed a reduced LORR duration
compared with wild-type animals and their LORR duration was
unaffected by pretreatment with NP078585. In contrast, the
LORRduration ofwild-type animalswas substantially attenuated
by pretreatment with NP078585 (Fig. 1C). A two-way ANOVA
showed main effects of both genotype (F(1,24)  40.17; p 
0.0001) and treatment (F(1,24) 27.69; p 0.0001) and an inter-
action between these factors (F(1,24) 14.43; p 0.007). Post hoc
Bonferroni tests revealed a specific effect of NP078585 in wild-
type animals only ( p 0.001).
NP078585 reduces ethanol reward and reinforcement
To investigate the effect of NP078585 on ethanol’s conditioned
motivational properties we examined ethanol-induced CPP in
mice. DBA/2 mice were trained in a standard ethanol CPP para-
digm consisting of four ethanol and four saline treatments on
intervening days (Newton et al., 2004; Newton and Messing,
2007). On the test day (no ethanol or saline treatment) animals
were given either vehicle or NP078585 (25 mg/kg) 30 min before
the preference test. Treatment with NP078585 abolished the ex-
pression of an ethanol CPP (Fig. 2A). Wilcoxon signed rank tests
revealed significant preference for the ethanol-paired side only in
animals pretreated with vehicle. Locomotor activity of mice in
the test chambers was not affected by NP078585 during the test.
Distance traveled (cm) for vehicle-treated mice was 514.7 
122.2 and for NP078585 treated mice was 423.4 120.1 An un-
paired t test comparing locomotor activity in the two groups
revealed no significant difference ( p  0.6). To determine
whether NP078585 caused a general impairment of the recall of a
conditioned stimulus we assessed the effect of NP078585 on the
expression of a lithium chloride conditioned place aversion. LiCl
produced a conditioned response similar in magnitude to that
Figure1. NP078585 reduces acutemotor effects of ethanol inmice.A, Pretreatmentwith 25
mg/kg NP078585 abolished the locomotor-stimulating effects of ethanol. Mice were injected
with either NP078585 (N) or vehicle (V) 30 min before 2 g/kg ethanol (E). Data was compared
between test day (Test, when ethanol was given) and the previous day (Base). B, Ethanol-induced
ataxia was attenuated on the accelerating rotarod. C, Pretreatment with 25 mg/kg NP078585 (NP)
reducedthedurationof theethanol (4g/kg)-inducedlossof therightingreflex inwild-type(WT)mice
but not inmice lackingN-type calcium channels (KO) (*p 0.05;n 9–10per group).
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obtained with ethanol. NP078585 did not affect the expression of
this conditioned place aversion.Wilcoxon signed rank tests revealed
a significant preference for the saline-paired side in animals pre-
treated with either vehicle or NP078585 (25mg/kg) (Fig. 2B).
Next we examined ethanol reinforcement by assessing the ef-
fects of NP078585 on operant self-administration of ethanol. We
used Long–Evans rats trained to self-administer0.3 g/kg etha-
nol in daily 30 min sessions (Monday through Friday) on an FR3
schedule. Mean responding after training was for 0.473 g/kg per
session, which in the Long–Evans rats used here would be ex-
pected to result in a blood alcohol concentration of 20–25 mg%,
approximately the level achieved by human social drinkers (Cza-
chowski et al., 1999; Gauvin, 1999; Roberts et al., 1999) Rats were
given vehicle, 2.5 or 25 mg/kg NP078585 30 min before the
Thursday operant session. Data from Tuesday and Wednesday
were averaged to calculate a baseline level of responding.
NP078585 pretreatment had no effect on operant responding on
the day it was given, but animals treatedwith 25mg/kgNP078585
showed a significant reduction in responding the day after treat-
ment (Friday) (Figs. 3A,B), and responding recovered to baseline
levels by the followingMonday (63.7 7.4 at baseline vs 74.62
9.0 on Monday, p  0.3 by paired t test). A two-way repeated-
measures ANOVA for lever pressing with a repeated measure for
time and a between-subjects factor for dose showed amain effect
of dose (F(2,40)  4.275; p  0.028) and an interaction between
treatment time and dose (F(4,40)  3.644; p  0.013). Post hoc
Bonferroni tests revealed a significant difference between 25
mg/kg and both vehicle ( p 0.001) and 2.5 mg/kg ( p 0.047)
NP078585 on the day after treatment, as well as a significant
difference between baseline and “day after” responding for the 25
mg/kg treatment ( p  0.032). A two-way repeated-measures
ANOVA for g/kg self-administered with a repeated measure for
time and a between-subjects factor for NP078585 dose showed a
main effect of dose (F(2,40) 7.607, p 0.0058) but no significant
effect of day and no interaction.However, comparing datawithin
“day after” by one-way ANOVA showed a significant difference
Figure 2. Expression of an ethanol conditioned place preference by DBA/2mice is abolished
by NP078585. A, NP078585 abolished the expression of ethanol conditioned place preference
when given on the test day. B, NP078585 did not affect the expression of a lithium chloride
conditioned place aversion (n 12 per group). *p 0.05 by Wilcoxon signed rank test.
Figure 3. NP078585 has a delayed inhibitory effect on operant ethanol self-administration
by Long–Evans rats. A, B, Data are presented as (A) amount of ethanol delivered in g/kg or (B)
active lever presses. NP078585 pretreatment had no effect on operant responding on the day it
was given, but animals treated with 25 mg/kg NP078585 showed a significant reduction in
responding the day after treatment. C, Responding on the inactive lever was not affected by
NP078585 (*p 0.05, n 11 per group)
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between 25 mg/kg and both vehicle and 2.5 mg/kg. Responding
on the inactive levers (Fig. 3C) was not affected by NP078585.
Stress-induced reinstatement to operant ethanol seeking
We used yohimbine to assess the effects of NP078585 on stress-
induced reinstatement to alcohol seeking. Yohimbine is an al-
pha2 adrenergic receptor antagonist that produces reinstatement
of extinguished operant ethanol seeking via a CRF-1 receptor-
dependent mechanism (Leˆ et al., 2005; Gass and Olive, 2007;
Marinelli et al., 2007). Rats were pretreated with either vehicle or
NP078585, 30 min before receiving yohimbine. Yohimbine pro-
duced a significant reinstatement of alcohol seeking in animals
pretreated with vehicle, but not in rats pretreated withNP078585
(Fig. 4A). A two-way repeated-measures ANOVAwith a between
subjects factor for pretreatment drug (NP078585 or vehicle) and
a repeated measure for behavioral state (extinction versus
yohimbine-induced reinstatement) showed a significantmain ef-
fect of pretreatment (F(1,17) 6.632; p 0.020) but not yohim-
bine (F(1,17) 3.345; p 0.085), although there was a significant
interaction between the two factors (F(1,17) 4.916; p 0.041).
Post hocBonferroni tests revealed a significant difference between
yohimbine and vehicle treatment in animals pretreated with ve-
hicle ( p  0.013) but not in animals pretreated with NP078585
( p  0.781). Although these data did not show homogenous
variances, the ANOVA is considered valid where sample sizes are
equal, or almost equal (Zar, 1984; Dawson-Saunders and Trapp,
1994). Nevertheless we also conducted a nonparametric analysis
to confirm our ANOVA results. There is no nonparametric
equivalent of a two-way repeated-measures ANOVA, so we used
the Wilcoxon signed-rank test as a nonparametric repeated-
measures test to compare the effects of yohimbine-induced rein-
statement in animals that had been treated with either vehicle or
NP078585. For rats pretreated with vehicle, the effect of yohimbine
was significant when compared with responding under extinction
conditions ( p0.05),whereas for those rats treatedwithNP078585
yohimbine had no effect ( p  0.492). These results confirm the
findings of the two-way ANOVA and demonstrate that NP078585
blocks yohimbine-induced reinstatement of ethanol seeking.
A possible caveat to these findings is that responding on the
previously inactive lever was reduced by the combination of
NP078585 and yohimbine (Fig. 4B). A two-way repeated-
measures ANOVA with factors for pretreatment and yohimbine
showed a significant effect of pretreatment ( p  0.038) but not
yohimbine ( p 0.434)with a significant interaction between the
two factors ( p  0.044). Post hoc Bonferroni tests revealed sig-
nificant effects of yohimbine within NP078585 treatment and of
pretreatment (vehicle vsNP078585)within yohimbine treatment
( p  0.05). To further investigate the effects of yohimbine and
NP078585 on locomotor activity, we performed a separate exper-
iment where locomotor activity was analyzed in a habituated
environment. Yohimbine stimulated locomotor activity relative
to vehicle treatment alone, a phenomenon that has been de-
scribed previously (Mason et al., 1998; Schroeder et al., 2003).
NP078585 prevented this stimulation, but did not reduce loco-
motor activity relative to vehicle and had no effect by itself (Fig.
4C). Analysis by one-way ANOVA revealed a significant differ-
ence (F(3,33)  8.207; p  0.05) with a post hoc Bonferroni test
demonstrating a significant difference between the vehicle yo-
himbine group versus all other groups ( p 0.05).
Ethanol clearance
To investigate whether NP078585 alters ethanol metabolism, we
measured blood alcohol levels 30, 90 and 180 min after injection
of 4 g/kg ethanol in wild-type F1 C57BL/6J 129/S4 hybridmice
that had been pretreated with 25 mg/kg NP078585 or vehicle.
These time points were chosen based on their relevance to the
acute sensitivity experiments described in Figure 1. It is our ex-
perience that peak blood ethanol concentrations are achieved at
30min using tail blood sampling in this strain ofmice (Newton et
al., 2004). Clearance of ethanol from the blood did not differ
between vehicle and NP078585 treated mice (Fig. 5). A two-way
ANOVA with a between-subjects factor for pretreatment and a
within-subjects factor for time showed no effect of pretreatment
(F(1,23) 1.272; p 0.279) but a significant effect of time (F(2,23)
 53.562; p 0.001) with no significant interaction between the
two factors (F(2,23)  0.197; p  0.822). Additionally, we have
previously shown that mice lacking N-type calcium channels
show no differences in the clearance of ethanol when compared
with their wild-type littermates (Newton et al., 2004).
Figure4. NP078585 prevents the reinstatement of operant ethanol seeking by the pharma-
cological stressor yohimbine. Long–Evans ratswere trained to self-administer ethanol and then
extinguished over a 6week period (Extinction). Respondingwas then reinstatedwith the phar-
macological stressor yohimbine (Reinstate). A, Responding on the “alcohol” lever (which had
previously been active before extinction) was significantly reinstated by yohimbine in PEG-400
pretreated animals (Veh), but this effect was abolished by pretreatment with 25 mg/kg
NP078585.B, Yohimbinedidnot increase respondingon the inactive lever, but the combination
of yohimbine and NP078585 reduced responding on the inactive lever (*p 0.05; n 9–10
pergroup).C, NP078585 (N)didnot alter locomotor activity relative to its vehicle (V). Yohimbine
(Y) stimulated locomotor activity, an effect that was abolished by NP078585 (*p 0.05; n
12 per group).
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Discussion
The purpose of this study was to test our hypothesis that N-type
calcium channels are a potential drug target for the treatment of
alcoholism. We hypothesized that an N-type calcium channel
antagonist would attenuate the acute intoxicating effects of eth-
anol and reduce alcohol reward, reinforcement, and reinstate-
ment. We observed that the mixed N- and T-type calcium chan-
nel antagonist NP078585 reduced the acute effects of ethanol and
abolished the expression of ethanol conditioned place preference
by mice. In rats, NP078585 abolished stress-induced reinstate-
ment of ethanol-seeking and had a delayed effect on operant
self-administration of ethanol; responding was not affected im-
mediately after NP078585 treatment, but it was reduced the day
after. These findings indicate that NP078585 reduces ethanol in-
toxication, reward, self-administration, and reinstatement, sup-
porting our hypothesis that N-type calcium channels contribute
to these behaviors.
Treatment with NP078585 alone was not sedating to rats or
mice, and no obvious behavioral side effects were observed.
NP078585 is the parent compound of a class of N-type calcium
channel inhibitors that have been investigated in human clinical
trials for the treatment of chronic pain, where they were well
tolerated (The Healthcare Marketing and Sales Network, March
20, 2006). Additional N-type calcium channel inhibitors are be-
ing developed for clinical use (Schroeder et al., 2006). These stud-
ies, together with the data presented here, suggest that novel
N-type calcium channel inhibitors be further investigated as can-
didate drugs for the treatment of alcoholism.
Prior behavioral experiments using snail toxins to inhibit cal-
cium channels are difficult to interpret because many of these
toxins cause motor impairment and toxicity in rodents (Olivera
et al., 1994). Despite this, a previous study investigating the role
of N-type calcium channels in hypnotic responses to ethanol
showed that intraventricular administration of -conotoxin
GVIA prolonged the ethanol-induced loss of the righting reflex
when given 4 h before ethanol in food-deprived rats (Brown et al.,
1993). The discrepancy between the data obtained in that study
and our data presented here may be related to the fact that
-conotoxin GVIA exhibits some off-target activities, including
inhibition of L-type calcium channels (McCleskey et al., 1987).
Brown et al. also observed an increase in both spontaneous and
evoked tremor after -conotoxin GVIA treatment, and these
motor side effects may have impaired the righting reflex. The
effects of -conotoxin GVIA on other ethanol-related behaviors
has not been investigated, perhaps because of the side effects
described above. Although NP078585 also inhibits T-type Ca2
channels in vitro, we did not observe any effects of NP078585 in
mice lacking N-type calcium channels that had been given a hyp-
notic dose of ethanol. These results indicate that in the loss of
righting-reflex paradigm, NP078585 is largely acting via N-type
channel blockade, although we cannot rule out the possibility
that NP078585 is acting through T-type calcium channels in
other paradigms.
We have previously shown, in experiments with the PC12 cell
line, that ethanol inhibits the function of N-type calcium chan-
nels (Solem et al., 1997). Thus pretreatment with an N-type cal-
cium channel antagonist might be expected to potentiate, rather
than antagonize, the acute effects of ethanol. There are a number
of potential explanations for this apparent confound. The cell
culture observations may not be relevant to the in vivo effects of
ethanol, where a number of other ion channels and second mes-
sengers are important (Narahashi et al., 2001; Newton andMess-
ing, 2006). Also the 1997 studywas conducted using-conotoxin
GVIA and is thus subject to the same caveats as described above.
Finally, as mentioned above NP078585may itself be acting through
targets other than N-type calcium channels in some paradigms.
Ethanol has repeatedly been demonstrated to increase neuro-
transmitter release at GABAergic synapses (Siggins et al., 2005).
Given the role of T-type calcium channels in mediating oscilla-
tory and rebound burst behaviors, together with the presynaptic
location of N-type channels and their demonstrated role in reg-
ulating GABA release at a number of different synapses (Tredway
et al., 1999; Poncer et al., 2000; Momiyama and Koga, 2001), it is
possible that the combined effects of blockingN- and T-type type
channels with NP078585 may be to inhibit ethanol-induced in-
creases in GABA release and so reduce the behavioral effects of
ethanol. This would also require that the inhibitor block only the
increase in GABA release seen after ethanol treatment without
affecting baseline release. Such a circumstance has been demon-
strated in chick brain slices, where -conotoxin GVIA pretreat-
ment blocks nicotinic acetylcholine receptor-mediated enhance-
ment of GABA release without affecting baseline release
(Tredway et al., 1999).
We observed that NP078585 abolished the expression of an
ethanol conditioned place preference inmice, a property it shares
with naltrexone (Middaugh and Bandy, 2000), which is the most
effective approved medication for the treatment of alcohol use
disorders (Anton et al., 2006). Because N-type calcium channels
have been postulated to play a role in learning andmemory (Jeon
et al., 2006), we determined whether NP078585 caused a general
impairment of the recall of a conditioned stimulus by assessing
the effect of NP078585 on the expression of a lithium chloride
conditioned place aversion. LiCl produced a conditioned re-
sponse similar in magnitude to that obtained with ethanol.
NP078585 did not affect the expression of this conditioned place
aversion, confirming that NP078585 does not produce a general
deficit in the recall of conditioned stimuli.
Our ethanol place preference data initially appear to be con-
trasted by the data from our operant self-administration experi-
ments with Long–Evans rats, where NP078585 did not alter op-
erant responding on the day it was given; these operant data
would suggest that NP078585 does not diminish motivation to
experience the effects of ethanol. There are a number of potential
explanations for the apparent discrepancy between these two re-
sults. They were derived from different paradigms and different
species, involving passive versus voluntary exposure to different
ethanol concentrations over very different durations. The debate
about similarities and differences between place preference and
Figure 5. NP078585 treatment does not alter the clearance of ethanol from the blood. Mice
were treated with vehicle or NP078585 (25 mg/kg) 30 min before ethanol (4 g/kg). Blood
alcohol concentration was assayed at the times indicated. There was no difference in clearance
between vehicle and NP078585 treated mice ( p  0.05 by two-way repeated-measures
ANOVA).
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operant self-administration experiments is a lengthy and ongo-
ing one (Sanchis-Segura and Spanagel, 2006; Tzschentke, 2007).
Perhaps the most attractive explanation is the difference in the
amounts of alcohol involved in the two experiments. In the con-
ditioned place preference assay, animals are motivated by the
subjective effects of an experimenter-administered 2 g/kg ethanol
injection which should result in blood alcohol concentrations of
100 mg% in DBA/2 mice (Chester and Cunningham, 1999),
which is a dose sufficient to cause significant intoxication. In the
operant self-administration experiment, Long–Evans rats were
trained to voluntarily self-administer 0.47 g/kg ethanol. Al-
though we did not measure blood alcohol concentrations in the
current study, published reports indicate that Long–Evans rats
self-administering this amount of alcohol attain a blood alcohol
concentrations of 20–25 mg%, approximately the level encoun-
tered by human social drinkers (Czachowski et al., 1999; Gauvin,
1999; Roberts et al., 1999). These data suggest that themotivation
to experience a lower dose of ethanol is not affected byNP078585,
whereas the motivation to experience a higher dose is attenuated
by this drug.
Although NP078585 did not decrease operant responding on
the day it was given, it did decrease responding on the following
day. Thus, the rewarding effects of a low dose of ethanol may be
diminished or its aversive effects enhanced when consumed un-
der the influence ofNP078585. A similar pattern is seen in studies
where human alcoholics are allowed to continue drinking while
taking naltrexone; alcohol intake declines gradually through a
process that is thought to be similar to extinction (Sinclair, 2001).
Studies involving repeated dosing of NP078585 during self-
administration will address whether NP078585 has similar ef-
fects. In animal studies, a similar pattern has been observed for
the effect of naloxone on the reinforcing properties of heroin in a
runway assay (McFarland and Ettenberg, 1998); naloxone had no
effect on the day it was administered, but respondingwas reduced
24 h later, suggesting that naloxone does not alter motivation to
seek heroin, but rather it diminishes the reinforcing effects of
heroin. Similar changes are seen in negative contrast paradigms
where animals are trained to stably respond for a fixed concen-
tration of sucrose (e.g., 32%). Devaluing the reinforcer by reduc-
ing the concentration of sucrose results in a decrease in consump-
tion (Grigson, 2000). All of these hypotheses are the subject of
ongoing studies.
Regardless of the differences, our observation that NP078585
reduces responding in two very different rodent models of etha-
nol reward and reinforcement (place preference and self-
administration) suggests that N-type calcium channel antago-
nists may be useful for reducing alcohol consumption in human
subjects and underscores the need to use multiple paradigms
when developing medications to treat alcoholism (Egli, 2005). In
the current study, our paradigm and species selection was de-
signed tomost effectively test whether anN-type calcium channel
antagonist may be useful as a treatment for alcoholism. This re-
sulted in the use of multiple strains and species which may cause
problems formechanistic interpretations as evidenced by the po-
tentially confounding data obtained in our place preference and
self-administration paradigms. We were unable to use a single
species throughout the study. We wished to use mice for the
simple reason that we were able to test NP078585 inmice lacking
N-type calcium channels. Although mice are able to learn the
operant ethanol self-administration procedure, it is our experi-
ence that more consistent data are obtained from the use of Lon-
g–Evans rats. Also, stress-induced reinstatement of operant eth-
anol seeking by mice does not appear to have been established as
amodel system, although context and cue-induced reinstatement
has been demonstrated (Tsiang and Janak, 2006) as well as stress-
induced increases in alcohol preference in a nonoperant para-
digm (Racz et al., 2003).
Stress is a significant precipitant of relapse in otherwise absti-
nent alcoholics (Brown et al., 1995). However, the development
ofmedications to specifically treat stress-induced relapse is prob-
lematic because many traditional anxiety medications, such as
benzodiazepines, have sedative effects that are additivewith those
of ethanol. Naltrexone does not attenuate stress-induced rein-
statement in rodents (Leˆ et al., 1999). Our finding that NP078585
completely blocked reinstatement induced by yohimbine sug-
gests that calcium channel antagonists, unlike currently available
drugs used to treat alcohol use disorders, may reduce stress-
induced relapse. It is interesting to note that yohimbine also stim-
ulated locomotor activity and that this stimulation was also
blocked by NP078585. Inactive lever presses were not stimulated
by yohimbine treatment so it seems unlikely that the reinstate-
ment of active lever pressing produced by yohimbine was a gen-
eral effect on locomotor activity. However, we cannot completely
rule out the possibility that yohimbine-stimulated increases in
locomotor activity contribute to increased responding on the
previously active lever and thus the ability of NP078585 to block
this locomotor increase may contribute to its ability to block
reinstatement of active lever pressing.
In summary, our results demonstrate that the N- and T-type
calcium channel antagonist NP078585 attenuates or abolishes
the acute effects of ethanol over a wide range of ethanol doses
(2–4 g/kg). NP078585 also reduces the conditionedmotivational
effects of an intoxicating dose of ethanol, decreases the reinforc-
ing effects of a low dose of ethanol, and blocks stress-induced
reinstatement of ethanol seeking. These data offer the attractive
possibility that human alcoholics treated with N-type or mixed
N- and T-type calcium channel inhibitors may become less mo-
tivated to experience the effects of ethanol, and those effects
might be reduced should they drink while under treatment.
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